Showing 113 results
-
Media Release /Approximately 90,000 Canadians live with multiple sclerosis (MS), a disease that impacts the central nervous system.1 Canada has one of the highest rates of MS in the world, with an average of 12…
-
Media Release /Fabhalta® (iptacopan capsules) is an oral Factor B inhibitor indicated for the treatment of adult patients with complement 3 glomerulopathy (C3G) to reduce proteinuria.1Phase III APPEAR-C3G…
-
Media Release /Montreal, March 30th, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) is calling on Canadian early‑career oncology clinicians and researchers to submit abstracts for the 2026 Novartis…
-
Media Release /Novartis has a long-standing history in Canada, and is committed to delivering improved outcomes for millions of patients. In 2022, Novartis invested a total of $450 million in Canada.The office has…
